<DOC>
	<DOCNO>NCT00294112</DOCNO>
	<brief_summary>Human mesenchymal stem cell ( MSCs ) , derive healthy adult volunteer human donor , obtain bone marrow donation culture laboratory . MSCs show ability find injured tissue , reduce control inflammation , assist tissue repair . Prochymal™ MSCs infuse patient moderate-to-severe Crohn 's disease . Infusions occur two separate day , 7-10 day apart . Patients monitor reduced Crohn 's disease symptom .</brief_summary>
	<brief_title>Prochymal™ Adult Human Mesenchymal Stem Cells Treatment Moderate-to-severe Crohn 's Disease</brief_title>
	<detailed_description>Human mesenchymal stem cell ( MSCs ) , derive healthy adult volunteer human donor , obtain bone marrow donation culture laboratory . MSCs show ability find injured tissue , reduce control inflammation , assist tissue repair . Prochymal™ MSCs infuse patient moderate-to-severe Crohn 's disease . Infusions occur two separate day , 7-10 day apart . Patients monitor reduced Crohn 's disease symptom . Patients receive high low dose . Study open label .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Subject must 18 70 year age , inclusive . 2 . If female childbearing age , subject must nonpregnant , nonbreastfeeding , use adequate contraception . If male , subject must use adequate contraception . 3 . Subject must endoscopically radiographically active Crohn 's disease 4 . Subject must Crohn 's disease activity index ( CDAI ) least 220 . 5 . Subject must Creactive protein ( CRP ) least 5 mg/l . 6 . Subject must ileocolitis , colitis , ileitis . 7 . At time course subject 's Crohn 's disease ( CD ) , subject must receive steroid immunosuppressive agent ( example , azothioprine , 6mercaptopurine , methotrexate ) control CD . 8 . Subject may receive antibiotic , 5aminosalicylic acid , azathioprine , 6mercaptopurine , methotrexate , prednisone , similar drug time enrollment . The dose 5aminosalicylic acid ( 5ASA ) must stable least 4 week prior enrollment . The dose steroid must stable least 4 week prior enrollment . The dose antibiotic must stable least 4 week prior enrollment . The dose immunosuppressant ( example , azathioprine , 6mercaptopurine [ 6MP ] , methotrexate ) must stable least 8 week prior enrollment subject therapy least three month prior enrollment . 9 . Subject must adequate renal function define calculated creatinine clearance great 30 ml/min use CockroftGault equation , serum creatinine concentration le 2.0 mg/dl . 10 . Subject must available specified assessment study site day 30 . 11 . Subject must provide write informed consent form ( ICF ) authorization use disclosure personal health information ( PHI ) . 1 . Subject alcohol substance abuse within 6 month randomization . 2 . Subject evidence fibrostenotic obstructive Crohn 's disease . 3 . Subject active infection HIV hepatitis B C. 4 . Subject surgery trauma within 28 prior enrollment . 5 . Subject know allergy compute tomography ( CT ) contrast agent . 6 . Subject know allergy bovine porcine product . 7 . Subject body mass great 150 kg . 8 . Subject stricture bowel require hospitalization within 6 month prior enrollment . 9 . Subject bowel surgery perianal ( example , fistulotomy , seton placement , abscess drainage ) within 6 month prior enrollment . 10 . Subject receive infliximab ; adalimumab ; antibody , protein , biological therapy specifically approve United States Food Drug Administration ( FDA ) Crohn 's disease 90 day ( ) prior enrollment study . 11 . Subject receive prednisone great 20 mg/d time 28 prior enrollment study . 12 . Subject permanent colostomy ileostomy . 13 . Subject AST , ALP , ALT 2.5 time upper limit normal screening . 14 . Subject evidence active malignancy resect basal squamous cell carcinoma skin , prior history active malignancy remission least 5 year . 15 . Subject history bacteremia serious bacterial fungal infection past 3 month treat urinary tract infection drain perianal abscess . 16 . Subject receive investigational agent ( IA ) —an agent device approve FDA market use indication—within 90 ( 5 halflives , whichever long ) randomization . 17 . Subject cardiopulmonary disease , opinion Investigator , either unstable severe enough justify exclusion study . 18 . Subject underlying current medical psychiatric condition , opinion Investigator , would make participation study unsafe . 19 . Subject underlying current medical psychiatric condition , opinion Investigator , would interfere evaluation subject . Such excluding condition might include , example , uncontrolled infection , right heart failure , pulmonary hypertension . 20 . Subject unstable arrhythmia . 21 . Subject unwilling unable adhere requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>mesenchymal stem cell</keyword>
</DOC>